ウェビナー動画：ADC Therapeutics社、バイオ医薬品の研究開発における包括的な統合データベースの導入展開
ADC Therapeutics社では、包括的なバイオ医薬品研究開発プラットフォームとしてGenedata Biologics®を活用しています。本動画では、同社のAssociate DirectorであるChristopher Gallagher Ph.D.氏が登壇し、抗体のスクリーニングやエンジニアリングから抗体薬物複合体（ADC）特有の分析まで、どのようにADCの創薬プロセスを効率化し、スループットを向上しているか紹介しています。
In this webinar, learn how ADC Therapeutics is streamlining the entire Antibody-Drug Conjugate (ADC) R&D process by using a central E2E digital backbone that enables the registration and tracking of both complex biologics and small molecules, integrating analytics and functional assay results into a ‘single source of truth’ across R&D, which significantly improves the throughput and efficiency of ADC discovery.
Christopher Gallagher, Ph.D., Associate Director at ADC Therapeutics (ADCT) will share how Genedata Biologics digitalizes and automates processes across ADC discovery — from antibody engineering to expression, purification, chemistry and conjugation, cell biology, and ADC characterization and QC.
Get Insights On:
- The entire process of ADC development from antibody engineering, expression, purification, and bioconjugation to characterization
- Enhancing discovery through comprehensive registration and tracking of all ADCs and their unique components including antibodies, linkers, payloads, DAR, and conjugation sites
- Capturing, analyzing, and visualizing in vitro and in vivo characterization data, including toxicology and PK studies, to more efficiently evaluate ADC batches
- Streamlining the ADC discovery process by integrating registration, analytics, functional assay results, and visualizations in a single source of truth
